GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Long-Term Capital Lease Obligation

Aditxt (Aditxt) Long-Term Capital Lease Obligation : $0.89 Mil (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Aditxt Long-Term Capital Lease Obligation?

Aditxt's Long-Term Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.89 Mil.

Aditxt's quarterly Long-Term Capital Lease Obligation declined from Sep. 2023 ($1.20 Mil) to Dec. 2023 ($1.04 Mil) and declined from Dec. 2023 ($1.04 Mil) to Mar. 2024 ($0.89 Mil).

Aditxt's annual Long-Term Capital Lease Obligation declined from Dec. 2021 ($2.77 Mil) to Dec. 2022 ($1.89 Mil) and declined from Dec. 2022 ($1.89 Mil) to Dec. 2023 ($1.04 Mil).


Aditxt Long-Term Capital Lease Obligation Historical Data

The historical data trend for Aditxt's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aditxt Long-Term Capital Lease Obligation Chart

Aditxt Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Long-Term Capital Lease Obligation
Get a 7-Day Free Trial - 0.86 2.77 1.89 1.04

Aditxt Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Long-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.66 1.42 1.20 1.04 0.89

Aditxt  (NAS:ADTX) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Aditxt Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Aditxt's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Aditxt (Aditxt) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aditxt Inc (NAS:ADTX) » Definitions » Long-Term Capital Lease Obligation
Traded in Other Exchanges
N/A
Address
737 North Fifth Street, Suite 200, Richmond, VA, USA, 23219
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes a tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues.
Executives
Charles Athle Nelson director 11-F, BUILDING 12, SUNKING PLAZA, GAOJIAO ROAD, HANGZHOU, ZHEJIANG F4 311122
Bnp Paribas Securities Corp 10 percent owner 787 SEVENTH AVE, NEW YORK NY 10019
Matthew Shatzkes officer: Chief Legal Officer and GC 737 N. FIFTH STREET, SUITE 200, RICHMOND VA 23219
Lauren Chung director 1620 BEACON STREET, OXNARD CA 93033
Thomas J Farley officer: PRINCIPAL ACCOUNTING OFFICER 2569 WYANDOTTE ST., SUITE 101, MOUNTAIN VIEW CA 94043
Jeffrey W. Runge director C/O PHARMATHENE, INC., ONE PARK PLACE, SUITE 450, ANNAPOLIS MD 21401
Rowena Albanna officer: CHIEF OPERATING OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Rosland Fisher Mcleod director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Pankovcin Corinne officer: CHIEF FINANCIAL OFFICER BUSINESS DEVELOPMENT CORP OF AMERICA, 405 PARK AVENUE, 14TH FLOOR, NEW YORK NY 10022
Laura E Anthony director LAURA ANTHONY, 120 S. OLIVE AVE, WEST PALM BEACH FL 33401
Namvar Kiaie director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Brian Michael Brady director 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354
Amro A. Albanna director, officer: CHIEF EXECUTIVE OFFICER 871 MARLBOROUGH AVENUE, SUITE 100, RIVERSIDE CA 92507
Shahrokh Shabahang director, officer: CHIEF INNOVATION OFFICER 11161 ANDERSON STREET, SUITE 105-10014, LOMA LINDA CA 92354

Aditxt (Aditxt) Headlines

From GuruFocus